|
INTEGRILIN ®是一种抗血栓剂，可逆性地抑制，防止纤维蛋白原结合的GP防爆-Ⅲa受体血小板聚集。 INTEGRILIN ®有助于防止动脉闭塞的冠状动脉，从而降低缺血性事件的发生率
學名:
Eptifibatide
商品牌子名:
INTEGRILIN INJ 0.75MG/ML
INTEGRILIN INJ 2MG/ML
藥物製造商:
Schering-Plough
劑型:
針劑
孕婦用藥分級: B
藥理:
Eptifibatide是靜脈注射血小板糖蛋白IIb/IIIa抑制劑(platelet glycoprotein IIb/IIIa inhibitor)，抑制這個受體可阻止血小板聚集及預防血栓形成
用途:
治療急性冠狀症候群(acute coronary syndrome)，包括以內科治療及進行冠狀動脈血管造型術（percutaneous coronary intervention）
劑量:
由靜脈注射(intravenous injection)及靜脈滴注(intravenous infusion)，劑量應由心臟科醫生決定
用藥禁忌:
1. 對Eptifibatide的任何成份有過敏反應
2. 有不正常出血，或過去三十天內曾有出血紀錄或中風
3. 嚴重高血壓而未經足夠治療及服用降高血壓藥物
4. 過去六星期內曾接受主要手術
5. 正在或計劃注射另一隻靜脈注射血小板糖蛋白IIb/IIIa抑制劑
6. 血小板過低(thrombocytopenia)
7. 正在接受洗腎人士
用藥注意:
出血為最常見的副作用，如出現嚴重出血，須立刻停止注射
常見副作用:
出血、低血壓、背痛、注射位置反應
其他副作用:
血小板過低(thrombocytopenia)
藥物相互作用:
其他影響止血(hemotasis)的藥物會增加Eptifibatide的藥效，需由醫生決定是否與此類藥物同時使用
醫管局藥物分類:
專用藥物
藥物法例分類:
P1S1S3（此藥為醫生處方藥物，須由藥劑師核實處方後配藥）
英國國家卓越臨床研究中心(NICE)建議：
二零零二年九月
建議血小板糖蛋白IIb/IIIa抑制劑：
1. 用於治療不穩定性心絞痛(unstable angina)或ST段不抬高的心肌梗塞(non-ST-segment-elevation myocardial infarction)。
2. 用於將接受冠狀動脈血管造型術（percutaneous coronary intervention）的高危人士，預防出現心肌梗塞或死亡。
3. 作為冠狀動脈血管造型術（percutaneous coronary intervention）的附屬藥物，當：
l 病人需接受冠狀動脈血管造型術，但手術延遲
l 病人為糖尿病(diabetes)患者
l 手術程序複雜
【原产地英文商品名】INTEGRILIN 75mg/100mls/vial
【原产地英文药品名】EPTIFIBATIDE
【中文参考商品译名】
注：以下产品是不同的价格和不同的规格，购买时请以电话咨询为准！
·INTEGRILIN 75毫克/100毫升/瓶
·INTEGRILIN 20毫克/10毫升/瓶
·INTEGRILIN 200毫克/100毫升/瓶
【中文参考药品译名】依菲巴特
【生产厂家中文参考译名】先灵
【生产厂家英文名】SCHERING
IMPORTANT PRESCRIBING AND SAFETY CONSIDERATIONS
Indications for INTEGRILIN® (eptifibatide) Injection:
For the treatment of patients with acute coronary syndrome (UA/NSTEMI), including patients who are
to be managed medically and those undergoing percutaneous coronary intervention (PCI)
For the treatment of patients undergoing percutaneous coronary intervention (PCI), including those
undergoing intracoronary stenting
Contraindicated in Patients With:
A history of bleeding diathesis or evidence of active abnormal bleeding within the previous 30 days
Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately
controlled on antihypertensive therapy
Major surgery within preceding 6 weeks
History of stroke within 30 days or any history of hemorrhagic stroke
Current or planned administration of another parenteral GP IIb-IIIa inhibitor
Dependency on renal dialysis
Known hypersensitivity to any component of the product
Precautions and Warnings:
In patients undergoing PCI, INTEGRILIN® (eptifibatide) Injection is associated with an increase in major and minor bleeding at the site of arterial sheath placement. Special care should be employed to minimize the risk of bleeding among these patients.
If bleeding cannot be controlled with pressure, infusion of INTEGRILIN® and concomitant heparin should be stopped immediately.
Because INTEGRILIN® inhibits platelet aggregation, caution should be employed when it is used with drugs that affect hemostasis, including thrombolytics, oral anticoagulants, NSAIDs, and dipyridamole.
Use with other GP IIb-IIIa inhibitors should be avoided.
INTEGRILIN® is cleared in part by the kidney and its plasma concentrations are doubled in patients with renal disease (creatinine clearance.
<50 mL/min). Therefore, the infusion dose of INTEGRILIN® needs to be reduced to 1 mcg/kg/min in these patients. INTEGRILIN® is contraindicated in patients who are dependent upon renal dialysis (please see dosing guidelines)
Caution should be exercised when administering eptifibatide to patients with a platelet count <100,000/mm3.
Bleeding is the most common complication encountered during INTEGRILIN® therapy. The majority of excess major bleeding events were localized at the femoral artery access site. Oropharyngeal, genitourinary, gastrointestinal, and retroperitoneal bleeding were seen more commonly with INTEGRILIN® compared with placebo. | 
